Core Viewpoint - Nutriband has selected a commercial worldwide brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit it to the FDA for approval [1][3] Group 1: Product Development - Nutriband's lead product utilizes AVERSA™ abuse deterrent technology, which aims to prevent the abuse and misuse of transdermal fentanyl [2][7] - The product has the potential to achieve peak annual US sales between $80 million to $200 million, with plans for development in major medical markets worldwide [3][9] Group 2: Branding and Regulatory Support - The company has partnered with Brand Institute, Inc. to develop the brand name and visual identity for the product, leveraging their expertise in pharmaceutical branding [2][5] - Drug Safety Institute, a subsidiary of Brand Institute, will provide regulatory services and support, staffed by former officials from major health agencies [6][11] Group 3: Intellectual Property - Nutriband's AVERSA™ technology is protected by a broad international intellectual property portfolio, with patents issued in 46 countries [7][8]